Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.

Inclusion Criteria: * Willing and able to sign informed consent * Greater than or equal to 18 years of age * Subjects with impaired 6 minute hall walk distance * Impaired quality of life as measured by Minnesota LWHF questionnaire * Ischemic cardiomyopathy without an acute coronary syndrome within the last 6 months * Residual well-demarcated region of LV systolic dysfunction defined as at least 3 consecutive segments of abnormal wall motion by echocardiography read at the echocardiography core laboratory * LVEF ≤40% measured by echocardiography read at the echocardiography core laboratory * Must meet wall thickness criteria * Subject has an implanted, functional AICD * Subjects with diabetes must have had an ophthalmologist exam within the last year showing no active proliferative retinopathy * Subject receiving stable optimal pharmacological therapy defined as: * ACE inhibitor and/or ARB, and Beta-blocker for 90 days with stable dose for 30 days unless contraindicated * Diuretic in subjects with evidence of fluid retention * ASA unless contraindicated * Statin unless contraindicated * Aldosterone antagonist per physician discretion Exclusion Criteria: * Planned revascularization within 30 days following enrollment * Estimated Glomerular Filtration Rate \< 30 ml/min\* * Signs of acute heart failure within 24 hours of scheduled injection * History of aortic valve regurgitation classified as "moderate" or severe * Moderate/Severe aortic stenosis defined as AVA \<1.5 cm2 Note: Patient should not be excluded if the patient's medical records document that within the last 6 months the patient has either: * no aortic stenosis * mild aortic stenosis * normal aortic valve * normal aortic pressure gradient * aortic pressure gradient \< 20 mmHg * Presence of an artificial aortic valve * Subjects with aortic aneurysm \>3.8 cm * Mitral regurgitation defined as "severe" measured by echocardiography at the clinical site. * Patients with planned mitral valve repair or replacement surgery * Any patient with a history of cancer will be excluded unless: * The cancer was limited to curable non-melanoma skin malignancies and/or * The cancer was removed by a successful tumor resection, with or without radiation or chemotherapy treatment, 5 years or more prior to enrollment in this study without recurrence Subjects must have the following results on age appropriate cancer screenings: * Subjects age 50 or older have had a Fecal occult blood test (FOBT) or fecal immunochemical test (FIT) that was negative within the last year * Women age 30 or older have had a PAP test that was negative within the last 3 years * Women age 40 or older have had a mammogram that was negative within the last year * Men above age 45 have had a Prostate-Specific Antigen (PSA) blood test and digital rectal examination (DRE) that was negative within the last year * At the request of the site principal investigator, any subject with a non-negative result thought to be due to a non-cancer-related condition will be evaluated by the medical monitor for enrollment Exclusion Criteria (ctd): * Subjects with persistent or chronic atrial fibrillation will be excluded unless: * A stable, regular heart rate is maintained with a biventricular pacemaker * A stable, regular heart rate is maintained with a univentricular pacemaker pacing less than or equal to 40% of the time * Subjects with Biventricular pacing device implant within the last 3 months OR previously implanted Biventricular pacing device with programming planned to be reoptimized following enrollment in this trial * Previous solid organ transplant * Subjects with greater than 40% univentricular RV Pacing * Subjects with uncontrolled diabetes defined as HbA1c \>9.0% * Inability to complete 6 minute walk or treadmill exercise test * Participation in an experimental clinical trial within 30 days prior to enrollment * Any subject who has been enrolled in a gene or stem cell therapy cardiac trial within the last year * Life expectancy of less than 1 year * Positive pregnancy test (serum βHCG) in women of childbearing potential and/or unwillingness to use contraceptives or limit sexual activity as described in Section 8.2.1 below * Unwillingness of men capable of fathering a child to agree to use barrier contraception or limit sexual activity as described in Section 8.2.1 below * Subjects who are breast feeding * Subjects with a positive test results for hepatitis B/C and/or HIV * Total Serum Bilirubin \>4.0 mg/dl * Aspartate aminotransferase (AST) \> 120 IU/L * Alanine aminotransferase (ALT) \> 135 IU/L * Alkaline phosphatase (ALP) \>300 IU/L * Clinically significant elevations in PT or PTT relative to laboratory norms * Any subject with a known existing LV thrombus or has an LV thrombus detected during the screening period of this study. * Subjects with Rutherford class 5 or 6 critical limb ischemia * Subject with severe chronic obstructive pulmonary disease (COPD) * Any subject requiring home oxygen use * Subjects with a history of Systemic Lupus Erythematosus (SLE) flare * History of drug or alcohol abuse within the last year * A subject will be excluded if he/she is unfit for the trial based on the discretion of the site Principal Investigator